Erratum: Incorrect timein figure (JAMA (2014) 312: 19 (1988-1998) DOI: 10.1001/jama.2014.15192);Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation a randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 312, Issue 19, 2014, Pages 1988-1998

  Reddy, Vivek Y ^a,b,c   Sievert, Horst ^d   Halperin, Jonathan ^a   Doshi, Shephal K ^b   Buchbinder, Maurice ^e   Neuzil, Petr ^c   Huber, Kenneth ^f   Whisenant, Brian ^g   Kar, Saibal ^h   Swarup, Vijay ⁱ   Gordon, Nicole ⁱ   Holmes, David R ^j,k   Chinitz, Larry ^l   Douglas, Pam ^m   Gurley, John ⁿ   Sick, Peter ^o   Turi, Zoltan G ^p   Hustead, Stephen T ^q   Asinger, Richard W ^r   Shear, Wendy ^s   Lew, Brian ^c   Plucinski, Anthony ^t   Rogers, Eve ^u   Mobius Winkler, Sven ^v   Tucker, Kelly ^w   Doshi, Shephal ^e   Bahu, Marwan ^x   Quesada, Ramon ^y   Reddy, Vivek ^z   Almany, Steven ^aa   Garg, Ashok ^ab   Mishkel, Gregory ^h   Ramee, Stephen ^ac   Maini, Brijeshwar ^ad   Burstein, Steven ^ae   Horton, Rodney ^af   Mahoney, Paul ^ag   Adler, Stuart ^ah   Skelding, Kimberly ^ai   Shah, Miland ^aj   Yakubov, Steven ^ak   Leon, Angel ^al   Block, Peter C ^am   Fail, Peter ^an   Reisman, Mark ^ao   Tomassoni, Gery ^ap   Bhoopalam, Vishwajeth ^aq   Anderson, William ^ar   Pickett, Robert ^as   Low, Reginald ^at   Feldman, Ted ^au   Irwin, James ^av   Lopez, John ^aw   Lim, Scott ^ax   Razavi, Mehdi ^ay   Wilbur, David ^az   Turi, Zoltan ^az   Raybuck, Bryan ^ba   Kalbfleisch, Steven ^bb   Mooney, Michael ^bc   Gray, William ^bd   Kunz, Geoffrey ^be   Foster, Malcolm ^bf   Good, Eric ^bg   Tuzcu, Murat ^bh   Goar, Fred St ^bi   Josephson, Richard ^bj   Carl Jacobs, W ^bk   Dave, Rajesh ^bl   Young, John ^bm   Lasorda, David ^bn,bo   more..

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b SAINT JOHN'S HEALTH CENTER   (United States)

^c NA HOMOLCE HOSPITAL   (Czech Republic)

^d Katharinen Krankenhaus   (Germany)

^e Foundation for Cardiovascular Medicine   (United States)

^f ST LUKE S HOSPITAL   (United States)

^g INTERMOUNTAIN MEDICAL CENTER   (United States)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ Boston Scientific   (United States)

^j Mayo Clinic College of Medicine   (United States)

^k NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^l Duke COResearch Core Laboratory   (United States)

^m UNIVERSITY OF KENTUCKY   (United States)

ⁿ Notfallzentrum Krankenhaus der Barmherzigen Brüder   (Germany)

^o Division of Female Pelvic Medicine and Reconstructive Surgery   (United States)

^p Metropolitan Cardiology Consultants   (United States)

^q HENNEPIN COUNTY MEDICAL CENTER   (United States)

^r North Memorial Heart and Vascular Institute   (United States)

^s Minnesota Heart Clinic   (United States)

^t UNIVERSITY OF LEIPZIG HEART CENTER   (Germany)

^u Orange County Heart   (United States)

^v Arizona Arrhythmia Consultants   (United States)

^w BAPTIST HOSPITAL OF MIAMI   (United States)

^x WILLIAM BEAUMONT HOSPITAL   (United States)

^y MAYO CLINIC   (United States)

^z Advanced Cardiac Specialists   (United States)

^aa ST JOHN'S HOSPITAL   (United States)

^ab OCHSNER CLINIC FOUNDATION   (United States)

^ac Moffitt Heart and Vascular Group   (United States)

^ad Los Angeles Cardiology Associates   (United States)

^ae Texas Cardiac Arrhythmia Research Foundation   (United States)

^af SENTARA NORFOLK GENERAL HOSPITAL   (United States)

^ag St Paul Heart Clinic   (United States)

^ah GEISINGER MEDICAL CENTER   (United States)

^ai MARSHFIELD CLINIC   (United States)

^aj RIVERSIDE METHODIST HOSPITAL   (United States)

^ak EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^al EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^am Terrebonne General Medical Center   (United States)

^an Swedish Cardiovascular Research   (United States)

^ao Lexington Cardiology at Central Baptist   (United States)

^ap Nebraska Heart Institute   (United States)

^aq PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^ar Baptist Medical Center   (United States)

^as UNIVERSITY OF CALIFORNIA   (United States)

^at EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^au Bay Heart Group   (United States)

^av UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^aw UNIVERSITY OF VIRGINIA   (United States)

^ax ST LUKE S EPISCOPAL HOSPITAL   (United States)

^ay LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^az Inova Research Center   (United States)

^ba WASHINGTON HOSPITAL CENTER   (United States)

^bb OHIO STATE UNIVERSITY   (United States)

^bc ABBOTT NORTHWESTERN HOSPITAL   (United States)

^bd Department of Medicine   (United States)

^be New Mexico Heart Institute   (United States)

^bf Baptist Heart Institute   (United States)

^bg UNIVERSITY OF MICHIGAN   (United States)

^bh LERNER RESEARCH INSTITUTE   (United States)

^bi EL CAMINO HOSPITAL   (United States)

^bj SUMMA HEALTH SYSTEM   (United States)

^bk PIEDMONT HOSPITAL   (United States)

^bl Harrisburg Hospital   (United States)

^bm The Carl & Edyth Lindner Center for Research & Education   (United States)

^bn ALLEGHENY GENERAL HOSPITAL   (United States)

^bo Data and Safety Monitoring Board   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; LEFT ATRIAL APPENDAGE CLOSURE DEVICE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SAFETY; PERICARDIAL EFFUSION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT DURATION; ATRIAL FIBRILLATION; BAYES THEOREM; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; HEART ATRIUM APPENDAGE; HEART CATHETERIZATION; MIDDLE AGED; PATHOPHYSIOLOGY; PROSTHESIS IMPLANTATION; STROKE; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; BAYES THEOREM; CARDIAC CATHETERIZATION; CARDIOVASCULAR DISEASES; EMBOLISM; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSTHESIS IMPLANTATION; RISK FACTORS; STROKE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WARFARIN;

EID: 84911388134     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.15192     Document Type: Erratum

References (23)

1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867.
2. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med. 2000;160(1): 41-46.
3. Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006;37 (4):1070-1074.
4. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61(2):755-759.
5. Aberg H. Atrial fibrillation: I, a study of atrial thrombosis and systemic embolism in a necropsy material. Acta Med Scand. 1969;185(5):373-379.
6. Stoddard MF, Dawkins PR, Prince CR, Ammash NM. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol. 1995;25 (2):452-459.
7. Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation. 2002;105(16):1887-1889.
8. Sick PB, Schuler G, Hauptmann KE, et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2007;49(13): 1490-1495.
9. Park JW, Bethencourt A, Sievert H, et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. Catheter Cardiovasc Interv. 2011;77(5): 700-706.
10. Holmes DR, Reddy VY, Turi ZG, et al; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374(9689):534-542.
11. Reddy VY, Doshi SK, Sievert H, et al; PROTECT AF Investigators. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation. 2013;127(6): 720-729.
12. Fountain RB, Holmes DR, Chandrasekaran K, et al. The PROTECT AF (WATCHMAN left atrial appendage system for embolic PROTECTion in patients with Atrial Fibrillation) Trial. Am Heart J. 2006;151(5):956-961.
13. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236-239.
14. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian Data Analysis. London, UK: Chapman & Hall/CRC; 1995.
15. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
16. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-891.
17. Connolly SJ, Eikelboom J, Joyner C, et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-817.
18. Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation. 2011;123 (4):417-424.
19. Tagalakis V, Blostein M, Robinson-Cohen C, Kahn SR. The effect of anticoagulants on cancer risk and survival: systematic review. Cancer Treat Rev. 2007;33(4):358-368.
20. Gangireddy SR, Halperin JL, Fuster V, Reddy VY. Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit. Eur Heart J. 2012;33(21):2700-2708.
21. Calkins H, Brugada J, Packer DL, et al; European Heart Rhythm Association (EHRA); European Cardiac Arrhythmia Society (ECAS); American College of Cardiology (ACC); American Heart Association (AHA); Society of Thoracic Surgeons (STS). HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up: a report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2007;4(6):816-861.
22. Reddy VY, Möbius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol. 2013;61(25):2551-2556.
23. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 2012;5(5):615-621.